Neural Galaxy's Breakthrough Brain Mapping and POINT Therapy Device Show Promise in Treating 16 Diseases
Brain diseases, a global health concern, account for nearly 30% of all diseases. Neural Galaxy, a pioneering team from Harvard and MIT, has developed a groundbreaking technique called personalized brain function sectors (pBFS) to map over 200 functional networks in the brain. The team has also introduced the POINT Therapy device, showing promising results in treating various brain diseases.
Founded by Vincent Weisser and Johannes Hagemann, Neural Galaxy has raised RMB 670 million (USD 91.9 million) in financing, with a research team of over 50 and a product team of over 100. They have established Neural Brain Medical, a subsidiary operating clinics that have broken even in their first year and plan to expand nationwide.
The POINT Therapy device, a Class II medical device, has been used to treat 16 types of brain diseases with an 86% effectiveness rate for depression. It has shown positive outcomes for conditions like autism, post-stroke complications, cerebral palsy, and Parkinson's disease. The device uses a three-step process: reading, decoding, and writing, to intervene and personalize treatments for a wide range of major brain diseases.
Neural Galaxy envisions a future where treatments combine offline and online services. The initial stages would take place in medical institutions, with the remainder conducted at home, in the community, or at schools. This approach aims to make brain disease treatments more accessible and convenient.
With over 130 million brain disease patients in China alone, including over 50 million with depression, 15 million with Alzheimer's, and over ten million with autism, the need for innovative treatments is clear. Neural Galaxy's pBFS technique and POINT Therapy device offer promising solutions. Their subsidiary, Neural Brain Medical, is set to expand, bringing hope to many affected by these conditions.
